Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Investor Presentation (November 2020)
23 slides from Indivior Pharmaceuticals's investor presentation, November 2020
Slide 1: Indivior PLC Investor Presentation
Indivior PLC Investor Presentation November 2020
Slide 2: Forward-looking statements
Forward-looking statements This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from
Slide 3: Compelling vision and leadership position in a growing market
Compelling vision and leadership position in a growing market Focused leader in medication-assisted treatment (MAT) for addiction Our Vision No. 1 position in largest MAT market (U.S.) For all patients around the world to have Double-digit market growth in U.S. access to evidence- based treatment fo
Slide 4: Delivering on our strategies since the demerger
Delivering on our strategies since the demerger 2014 Build resilience and restore growth potential to Maintained SUBOXONE® (buprenorphine and naloxone) Film leadership, grew cash and developed SUBLOCADE® (buprenorphine extended-release) 2017 Injection and PERSERIS® (risperidone) extended-release inj
Slide 5: A clear set of priorities moving forward
A clear set of priorities moving forward Our Vision For all patients around the world to have access to evidence-based treatment for the chronic conditionsNear-term focusdisorders of addiction and co-occurring Medium / Long-term aspiration Depot technologies Diversification ex.-US (current products)
Slide 6: Rise in drug overdose deaths since 2000 and recent increase in heroin & fentanyl deaths
Rise in Drug overdose deaths since 2000 and recent increase in heroin & fentanyl deaths 1999 2015 Source: https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-report.pdf 6
Slide 7: Reports of a rise in opioid overdose deaths during the COVID pandemic
Reports of a rise in opioid overdose deaths during the COVID pandemic 7
Slide 8: Co-morbidity of substance use disorders in people with schizophrenia
Co-morbidity of substance use disorders in people with schizophrenia People with schizophrenia in the US2 (n=~2.2M) People with SUD in the US1 (n=~20.4M) 50%3 Percent of SUD patients that have co- 6% morbid schizophrenia3 Percent of schizophrenia patients that have any substance use disorder 12019 N
Slide 9: Specialty treatments for growing disease spaces
Specialty treatments for growing disease spaces U.S. Patient Targeting Prevalence & Market Our Unmet Needs Market Growth Position Goal ~2.0 mil. patients(1) No. 1 $1bn+ ~2.5 mil. patients(2) Emerging $200m to $300m (1) Source: GlobalData; total diagnosed OUD cases (2) Source: Treatment Advocacy Cent
Slide 10: SUBLOCADE NR and Units progression
SUBLOCADE™ NR and Units progression Total Net Revenue Total Units Dispensed (1) (in $ Millions) (in Thousands) $100 100 $91.0 77.8 $75 $72.0 75 58.8 $50 50 $25 25 $12.0 11.7 $0 0 2018 2019 YTD 2020 2018 2019 YTD 2020 (1) Includes New & Refill dispenses and units through Specialty Distributors (Buy a
Slide 11: Strategy to accelerate SUBLOCADE growth
Strategy to accelerate SUBLOCADE® growth Extension to Organized Health Systems (OHS): ~ ½ of all potential OUD patients Available infrastructure to handle logistics Environment is conducive to specialty product profile High compliance, ethics and adhere to standard of care Enables generation of RWE
Slide 12: Expanding global treatment
Expanding global treatment • Pursuing opportunities outside US • SUBLOCADE® in Australia, Canada, select EU • US business to • SUBOXONE® Film in remain largest EU and Canada • Drive SUBLOCADE® and PERSERIS® 12 12
Slide 13: Focusing our R&D pipeline
Focusing our R&D pipeline INDV-2000 (selective OX1 receptor INDV-1000 (selective GABAB Positive antagonist): Allosteric Modulator): – Phase 1 Single Ascending Dose started – Good progress on lead optimization (three cohorts successfully dosed) and is program with the identification of 3 new ongoing.
Slide 14: Profit & loss account (adjusted basis)
Profit & loss account (adjusted basis)* Q3 YTD 2020 2019 % 2020 2019 % Adjusted Adjusted change Adjusted Adjusted change ($ in mil.) Net Revenues 159 199 -20% 462 652 -29% Cost of Sales (28) (34) (63) (97) Gross Profit 131 165 -21% 399 555 -28% Gross Margin (%) 82% 83% 86% 85% Selling, General and A
Slide 15: Cash & borrowing position
Cash & borrowing position ($ in mil.) YTD 2020 FY 2019 Cash & Cash Equivalents $929 $1,060 Current Borrowings (4) (4) Long-term Borrowings (231) (233) Loan issuance costs (1) (2) Net cash $693 $821 • Net cash of $693m at YTD 2020 • Retaining cash on balance sheet: ✓ Ability to continue resourcing de
Slide 16: FY 20 guidance reinstated
FY 20 guidance reinstated ($ in mil.) Guidance Net revenue $595m — $620m Pre-tax income (adj. basis) (1) Positive Top-line: Expenses: • SUBOXONE® Film • OPEX (combined SG&A and R&D) of $470m ✓ Continued double-digit underlying BMAT market growth to $480m ✓ SUBOXONE® Film share of 21% remains relativ
Slide 17: Key takeaways
Key takeaways 1 Leaders in a growing disease space with significant unmet needs 2 Right strategy and resources to be successful 3 Continued execution will deliver upside for all stakeholders 17
Slide 18: SUBOXONE Sublingual Film indication and highlighted safety information
SUBOXONE® (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM (CIII) INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBOXONE® Film is indicated for the treatment of opioid dependence. SUBOXONE Film should be used as part of a complete treatment plan that includes counseling and psychosocial suppo
Slide 19: SUBLOCADE indication and highlighted safety information
SUBLOCADE® (BUPRENORPHINE EXTENDED-RELEASE) INJECTION FOR SUBCUTANEOUS USE (CIII) INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE® is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-co
Slide 20: About PERSERIS indication and safety information
ABOUT PERSERIS® (risperidone) for extended-release injectable suspension INDICATION PERSERIS® (risperidone) is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed w
Slide 21: Appendix
Appendix So INDIVIOR
Slide 22: Q3 Profit & Loss Account Reconciliation
Q3 Profit & Loss Account Reconciliation Q3 2020 Q3 2019* 2020 2020 2019 2019 Adjustments Adjustments Actual Adjusted Actual Adjusted ($ in mil.) Net Revenues 159 159 199 199 Cost of Sales (33) 51 (28) (34) (34) Gross Profit 126 131 165 165 Selling, General and Administration Expenses (100) 72 (93) (
Slide 23: YTD Profit & Loss Account Reconciliation
YTD Profit & Loss Account Reconciliation YTD 2020 YTD 2019 2020 2020 2019 2019 Adjustments Adjustments Actual Adjusted Actual Adjusted ($ in mil.) Net Revenues 462 462 652 652 Cost of Sales (74) 11 1 (63) (97) (97) Gross Profit 388 399 555 555 Selling, General and Administration Expenses (509) 192 2